Search results

There are 19 search results.
October 18, 2018

Causes of regional variation in Dutch healthcare expenditures: evidence from movers

We assess the relative importance of demand and supply factors as determinants of regional variation in healthcare expenditures in the Netherlands. Our empirical approach follows individuals who migrate between regions. We use individual data on annual healthcare expenditures for the entire Dutch population between the years 2006 and 2013.

No title
July 10, 2018

Analyse actieprogramma ‘Werken in de Zorg’

Het CPB heeft op verzoek van PVV, GroenLinks, SP, PvdA, 50PLUS, DENK, SGP en FVD het actieprogramma ‘Werken in de zorg’ geanalyseerd. Naast de budgettaire effecten komen ook de programma-effecten (het effect op de werkgelegenheid in de zorg) van het actieprogramma aan bod.

March 29, 2018

Does managed competition constrain hospitals’ contract prices? Evidence from the Netherlands

In the Dutch health care system health insurers negotiate with hospitals about the pricing of hospital products in a managed competition framework. In this paper, we study these contract prices that became for the first time publicly available in 2016. The data show substantive price variation between hospitals for the same products, and within a hospital for the same product across insurers.

December 7, 2017

Cost-Sharing Design Matters: A Comparison of the Rebate and Deductible in Healthcare

Since 2006, the Dutch population has faced two different cost-sharing schemes in health insurance for curative care: a mandatory rebate of 255 euros in 2006 and 2007, and since 2008 a mandatory deductible. Using administrative data for the entire Dutch population, we compare the effect of both cost-sharing schemes on healthcare consumption between 2006 and 2013.

October 12, 2017

Premium levels and demand response in health insurance: relative thinking and zero-price effects

In health care systems with a competitive health insurance market, governments or other sponsors (e.g. employers) often subsidize premiums to encourage enrolment. These subsidies are typically independent of plan choice leaving the absolute premium differences in place so as not to distort consumer choice of plan.

May 18, 2017

De introductie van dure technologie in de zorg

Nieuwe medische technologie kan veel gezondheidswinst opleveren. Toch is niet altijd even duidelijk of en in welke mate er sprake is van gezondheidswinst.

May 18, 2017

De introductie van dure technologie in de zorg: analysekader en case studies

Adoptie van nieuwe medische technologie kan veel gezondheidswinst opleveren en op die manier bijdragen aan de kwaliteit van zorg. Maar de introductie van nieuwe technologie kan ook de zorgkosten opdrijven en daarmee de betaalbaarheid van zorg in gevaar brengen.

February 24, 2017

Switching gains and health plan price elasticities: 20 years of managed competition reforms in the Netherlands

In this paper we estimate health plan price elasticities and financial switching gains for consumers over a 20 years period in which managed competition was introduced in the Dutch health insurance market.

November 24, 2016

Keuzegedrag verzekerden en risicosolidariteit bij vrijwillig eigen risico

VWS heeft in een verzoek aan het CPB een aantal vragen gesteld over het vrijwillig eigen risico in de zorg.